Kynurenines: from the perspective of major psychiatric disorders

Aye-Mu Myint*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Psychiatric disorders are documented to be associated with a mild pro-inflammatory state. Pro-inflammatory mediators could activate the tryptophan breakdown and kynurenine pathway with a shift toward the neurotoxic arm where excitotoxic N-methyl-D-aspartate receptor agonist quinolinic acid is formed. An unbalanced metabolism in terms of neuroprotective and neurotoxic effects, such as reduced kynurenic acid to kynurenine ratio, has been demonstrated in the major psychiatric disorders such as unipolar depression, bipolar manic-depressive disorder and schizophrenia, and in drug-induced neuropsychiatric side effects such as interferon-? treated patients. The changes in serum or plasma are shown to be associated with central changes such as in the cerebrospinal fluid and certain brain areas. While currently available antidepressants and mood stabilizers could not efficiently improve these neurochemical changes within the same period that could induce clinical improvement, some antipsychotic treatments could reverse certain metabolic imbalances. Some of these changes were tested also in animal models. In this review the role of this unbalanced kynurenine metabolism through interactions with other neurochemicals is discussed as a major contributing pathophysiological mechanism in psychiatric disorders. Moreover, the biomarker role of kynurenine metabolites and future therapeutic opportunities are also discussed.? 2012 The Author Journal compilation ? 2012 FEBS.
Original languageEnglish
Pages (from-to)1375-1385
JournalFEBS Journal
Issue number8
Publication statusPublished - Apr 2012


  • bipolar
  • depression
  • inflammation
  • kynurenine
  • kynurenic acid
  • NMDA
  • psychiatry
  • quinolinic acid
  • schizophrenia
  • tryptophan

Cite this